Artelo Biosciences announces preclinical efficacy results of ART26.12

Artelo Biosciences (ARTL) announced the presentation of preclinical data in an osteaoarthritis pain model on its lead fatty acid binding protein 5 nhibitor, ART26.12, at the 35th Annual International Cannabinoid Research Society Symposium, being held July 6-10 in Bloomington, Indiana. The presentation, titled “The Fatty Acid Binding Protein 5 Inhibitor ART26.12 Alleviates Osteoarthritis Pain,” was delivered on July 8th by Dr. Martin Kaczocha, Assistant Professor in the Departments of Anesthesiology, Biochemistry and Cell Biology at Stony Brook University, New York. Dr. Kaczocha was the lead researcher for the OA study and serves as a scientific advisor at Artelo. The results demonstrated that ART26.12, a first-in-class, non-opioid, non-steroidal analgesic drug candidate, significantly alleviated pain associated with OA in preclinical models, in which a direct effect on plasma levels of relevant endocannabinoids was also observed. In these OA studies with ART26.12, the FABP5 inhibitor demonstrated efficacy comparable to naproxen, a commonly prescribed nonsteroidal anti-inflammatory drug, with ART26.12 maintaining analgesic efficacy throughout a four-week period of chronic dosing. Importantly, this extended administration did not result in the development of tolerance or diminished activity, a positive attribute that supports ART26.12’s potential in long-term treatment scenarios. From a safety perspective, ART26.12 may offer advantages over NSAIDs, which are collectively associated with gastrointestinal side effects in approximately one-third of patients receiving NSAIDs and are linked to a five-fold increase in gastric ulcer complications. ART26.12’s distinct pharmacological profile and utilization of endocannabinoids has the potential to provide a more favorable therapeutic option for patients requiring ongoing pain relief.